Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Vanda Pharma closes enrollment in ODYSSEY study » 07:27
08/03/21
08/03
07:27
08/03/21
07:27
VNDA

Vanda Pharmaceuticals

$16.89 /

+0.56 (+3.43%)

Vanda Pharmaceuticals…

Vanda Pharmaceuticals announced that enrollment has closed in the ODYSSEY study comparing tradipitant and placebo in hospitalized COVID-19 pneumonia patients. Enrollment was closed because the study met the pre-defined futility criteria, indicating that the study was unlikely to succeed in its pre-specified primary endpoint. The study was designed to determine whether tradipitant plus standard of care is superior to placebo plus standard of care in treating hospitalized patients with COVID-19 pneumonia who required supplemental oxygen support. The primary endpoint of the study is the difference between treatment and placebo on time to 2-point improvement on a 7-point ordinal scale. Treatment duration was 14 days and evaluation for the primary endpoint was at Day 28. Additional secondary endpoints include other changes in clinical and laboratory status.

ShowHide Related Items >><<
VNDA Vanda Pharmaceuticals
$16.89 /

+0.56 (+3.43%)

05/12/21
Fly Intel: Top five analyst initiations
05/12/21 BofA
BofA starts 'multi-product pipeline play' Vanda Pharmaceuticals at Buy
05/12/21 BofA
Vanda Pharmaceuticals initiated with a Buy at BofA
02/11/21 Citi
Vanda Pharmaceuticals price target raised to $18 from $14 at Citi
VNDA Vanda Pharmaceuticals
$16.89 /

+0.56 (+3.43%)

Earnings
Vanda Pharmaceuticals sees FY21 revenue $270M-$300M, consensus $282.92M » 17:03
07/28/21
07/28
17:03
07/28/21
17:03
VNDA

Vanda Pharmaceuticals

$19.49 /

+0.2 (+1.04%)

Sees year end cash…

Sees year end cash greater than $400M.

ShowHide Related Items >><<
VNDA Vanda Pharmaceuticals
$19.49 /

+0.2 (+1.04%)

05/12/21
Fly Intel: Top five analyst initiations
05/12/21 BofA
BofA starts 'multi-product pipeline play' Vanda Pharmaceuticals at Buy
05/12/21 BofA
Vanda Pharmaceuticals initiated with a Buy at BofA
02/11/21 Citi
Vanda Pharmaceuticals price target raised to $18 from $14 at Citi
VNDA Vanda Pharmaceuticals
$19.49 /

+0.2 (+1.04%)

Earnings
Vanda Pharmaceuticals reports Q2 EPS 17c, consensus 14c » 17:02
07/28/21
07/28
17:02
07/28/21
17:02
VNDA

Vanda Pharmaceuticals

$19.49 /

+0.2 (+1.04%)

Reports Q2 revenue…

Reports Q2 revenue $67.9M, consensus $69.75M. "Vanda had another outstanding quarter of commercial revenue growth as we resumed activity across a number of our clinical programs. Our tradipitant in gastroparesis program is nearing completion, bringing us closer to a much-needed new treatment option for patients with gastroparesis and a potentially transformational commercial opportunity for Vanda," said Mihael H. Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board.

ShowHide Related Items >><<
VNDA Vanda Pharmaceuticals
$19.49 /

+0.2 (+1.04%)

05/12/21
Fly Intel: Top five analyst initiations
05/12/21 BofA
BofA starts 'multi-product pipeline play' Vanda Pharmaceuticals at Buy
05/12/21 BofA
Vanda Pharmaceuticals initiated with a Buy at BofA
02/11/21 Citi
Vanda Pharmaceuticals price target raised to $18 from $14 at Citi
VNDA Vanda Pharmaceuticals
$19.49 /

+0.2 (+1.04%)

Over a quarter ago
Initiation
Fly Intel: Top five analyst initiations » 09:56
05/12/21
05/12
09:56
05/12/21
09:56
TSP

TuSimple

$37.44 /

-0.64 (-1.68%)

, VNDA

Vanda Pharmaceuticals

$18.00 /

+0.25 (+1.41%)

, NYMT

New York Mortgage

$4.38 /

+0.025 (+0.57%)

, CCEP

Coca-Cola Europacific Partners

$57.40 /

+1.235 (+2.20%)

, ASPN

Aspen Aerogels

$18.14 /

-0.03 (-0.17%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. TuSimple (TSP) initiated with an Outperform at Credit Suisse. 2. Vanda Pharmaceuticals (VNDA) initiated with a Buy at BofA. 3. New York Mortgage (NYMT) initiated with a Buy at B. Riley. 4. Coca-Cola European Partners (CCEP) reinstated with a Neutral at Goldman Sachs. 5. Aspen Aerogels (ASPN) assumed with an Outperform at Northland. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
VNDA Vanda Pharmaceuticals
$18.00 /

+0.25 (+1.41%)

TSP TuSimple
$37.44 /

-0.64 (-1.68%)

CCEP Coca-Cola Europacific Partners
$57.40 /

+1.235 (+2.20%)

ASPN Aspen Aerogels
$18.14 /

-0.03 (-0.17%)

TSP TuSimple
$37.44 /

-0.64 (-1.68%)

05/12/21 Credit Suisse
TuSimple initiated with an Outperform at Credit Suisse
05/11/21 Oppenheimer
TuSimple initiated with an Outperform at Oppenheimer
05/11/21 Wolfe Research
TuSimple initiated with a Peer Perform at Wolfe Research
05/10/21
Fly Intel: Top five analyst initiations
VNDA Vanda Pharmaceuticals
$18.00 /

+0.25 (+1.41%)

05/12/21 BofA
BofA starts 'multi-product pipeline play' Vanda Pharmaceuticals at Buy
05/12/21 BofA
Vanda Pharmaceuticals initiated with a Buy at BofA
02/11/21 Citi
Vanda Pharmaceuticals price target raised to $18 from $14 at Citi
01/14/21 Citi
Vanda Pharmaceuticals downgraded to Neutral from Buy at Citi
NYMT New York Mortgage
$4.38 /

+0.025 (+0.57%)

05/12/21 B. Riley
New York Mortgage initiated with a Buy at B. Riley
11/23/20 BTIG
New York Mortgage initiated with a Neutral at BTIG
11/11/20 Maxim
New York Mortgage upgraded to Buy from Hold at Maxim
05/27/20 Barclays
New York Mortgage upgraded to Equal Weight on stabilization at Barclays
CCEP Coca-Cola Europacific Partners
$57.40 /

+1.235 (+2.20%)

05/12/21 Goldman Sachs
Coca-Cola European Partners reinstated with a Neutral at Goldman Sachs
05/12/21 Deutsche Bank
Coca-Cola European Partners upgraded to Buy from Hold at Deutsche Bank
05/05/21 Exane BNP Paribas
Coca-Cola European Partners initiated with a Neutral at Exane BNP Paribas
02/23/21 Societe Generale
Coca-Cola European Partners downgraded to Sell from Hold at Societe Generale
ASPN Aspen Aerogels
$18.14 /

-0.03 (-0.17%)

05/12/21 Northland
Aspen Aerogels assumed with an Outperform at Northland
04/26/21 B. Riley
Aspen Aerogels resumed with a Buy at B. Riley
02/22/21 B. Riley
Aspen Aerogels price target raised to $30 from $19 at B. Riley Securities
02/19/21 Canaccord
Aspen Aerogels price target raised to $32 from $16 at Canaccord
VNDA Vanda Pharmaceuticals
$18.00 /

+0.25 (+1.41%)

TSP TuSimple
$37.44 /

-0.64 (-1.68%)

NYMT New York Mortgage
$4.38 /

+0.025 (+0.57%)

ASPN Aspen Aerogels
$18.14 /

-0.03 (-0.17%)

  • 15
    Apr
TSP TuSimple
$37.44 /

-0.64 (-1.68%)

VNDA Vanda Pharmaceuticals
$18.00 /

+0.25 (+1.41%)

TSP TuSimple
$37.44 /

-0.64 (-1.68%)

ASPN Aspen Aerogels
$18.14 /

-0.03 (-0.17%)

TSP TuSimple
$37.44 /

-0.64 (-1.68%)

Initiation
BofA starts 'multi-product pipeline play' Vanda Pharmaceuticals at Buy » 07:29
05/12/21
05/12
07:29
05/12/21
07:29
VNDA

Vanda Pharmaceuticals

$17.80 /

-0.05 (-0.28%)

As previously reported,…

As previously reported, BofA analyst Olivia Brayer initiated coverage of Vanda Pharmaceuticals with a Buy rating and $22 price target. Vanda is a CNS-focused biopharma company with two core assets, Fanapt and Hetlioz, that is already profitable and is now transitioning to "a multi-product pipeline play" with over six phase 3 programs ranging from label expansions and newer pipeline products, Brayer tells investors. Vanda tends to "fly under the radar given past regulatory setbacks," but it is now in a good position for what should be a turning point in the story into the second half of 2021, Brayer argues.

ShowHide Related Items >><<
VNDA Vanda Pharmaceuticals
$17.80 /

-0.05 (-0.28%)

VNDA Vanda Pharmaceuticals
$17.80 /

-0.05 (-0.28%)

05/12/21 BofA
Vanda Pharmaceuticals initiated with a Buy at BofA
02/11/21 Citi
Vanda Pharmaceuticals price target raised to $18 from $14 at Citi
01/14/21 Citi
Vanda Pharmaceuticals downgraded to Neutral from Buy at Citi
12/03/20 Jefferies
Vanda Pharmaceuticals price target raised to $18 from $16 at Jefferies
VNDA Vanda Pharmaceuticals
$17.80 /

-0.05 (-0.28%)

VNDA Vanda Pharmaceuticals
$17.80 /

-0.05 (-0.28%)

Initiation
Vanda Pharmaceuticals initiated with a Buy at BofA » 06:04
05/12/21
05/12
06:04
05/12/21
06:04
VNDA

Vanda Pharmaceuticals

$17.80 /

-0.05 (-0.28%)

BofA initiated coverage…

BofA initiated coverage of Vanda Pharmaceuticals with a Buy rating and $22 price target.

ShowHide Related Items >><<
VNDA Vanda Pharmaceuticals
$17.80 /

-0.05 (-0.28%)

VNDA Vanda Pharmaceuticals
$17.80 /

-0.05 (-0.28%)

02/11/21 Citi
Vanda Pharmaceuticals price target raised to $18 from $14 at Citi
01/14/21 Citi
Vanda Pharmaceuticals downgraded to Neutral from Buy at Citi
12/03/20 Jefferies
Vanda Pharmaceuticals price target raised to $18 from $16 at Jefferies
10/29/20 Citi
Vanda Pharmaceuticals upgraded to Buy from Neutral at Citi
VNDA Vanda Pharmaceuticals
$17.80 /

-0.05 (-0.28%)

VNDA Vanda Pharmaceuticals
$17.80 /

-0.05 (-0.28%)

Earnings
Vanda Pharmaceuticals sees FY21 revenue $270M-$300M, one estimate $283.4M  16:28
05/05/21
05/05
16:28
05/05/21
16:28
VNDA

Vanda Pharmaceuticals

$16.57 /

-0.07 (-0.42%)

 
ShowHide Related Items >><<
VNDA Vanda Pharmaceuticals
$16.57 /

-0.07 (-0.42%)

VNDA Vanda Pharmaceuticals
$16.57 /

-0.07 (-0.42%)

02/11/21 Citi
Vanda Pharmaceuticals price target raised to $18 from $14 at Citi
01/14/21 Citi
Vanda Pharmaceuticals downgraded to Neutral from Buy at Citi
12/03/20 Jefferies
Vanda Pharmaceuticals price target raised to $18 from $16 at Jefferies
10/29/20 Citi
Vanda Pharmaceuticals upgraded to Buy from Neutral at Citi
VNDA Vanda Pharmaceuticals
$16.57 /

-0.07 (-0.42%)

VNDA Vanda Pharmaceuticals
$16.57 /

-0.07 (-0.42%)

Earnings
Vanda Pharmaceuticals reports Q1 EPS 15c, one estimate 15c » 16:27
05/05/21
05/05
16:27
05/05/21
16:27
VNDA

Vanda Pharmaceuticals

$16.57 /

-0.07 (-0.42%)

Reports Q1 revenue…

Reports Q1 revenue $62.7M, one estimate $68.5M.Cash, cash equivalents and marketable securities was $378.2M as of March 31, representing an increase to cash of $65.8M a year ago. "Despite seasonal and global challenges, we recorded another quarter of strong revenue across our commercial portfolio coupled with the launch of Hetlioz in the new indication of nighttime sleep disturbances in patients with Smith-Magenis Syndrome," said Mihael Polymeropoulos. "In our clinical programs, we have made significant progress, reaching 85% randomization in our Phase III tradipitant study in gastroparesis and initiating a new clinical program for Hetlioz in delayed sleep phase disorder."

ShowHide Related Items >><<
VNDA Vanda Pharmaceuticals
$16.57 /

-0.07 (-0.42%)

VNDA Vanda Pharmaceuticals
$16.57 /

-0.07 (-0.42%)

02/11/21 Citi
Vanda Pharmaceuticals price target raised to $18 from $14 at Citi
01/14/21 Citi
Vanda Pharmaceuticals downgraded to Neutral from Buy at Citi
12/03/20 Jefferies
Vanda Pharmaceuticals price target raised to $18 from $16 at Jefferies
10/29/20 Citi
Vanda Pharmaceuticals upgraded to Buy from Neutral at Citi
VNDA Vanda Pharmaceuticals
$16.57 /

-0.07 (-0.42%)

Recommendations
Vanda Pharmaceuticals price target raised to $18 from $14 at Citi » 06:25
02/11/21
02/11
06:25
02/11/21
06:25
VNDA

Vanda Pharmaceuticals

$15.43 /

-0.01 (-0.06%)

Citi analyst Joel Beatty…

Citi analyst Joel Beatty raised the firm's price target on Vanda Pharmaceuticals to $18 from $14 and keeps a Neutral rating on the shares following the company's Q4 results. The most notable takeaway from earnings is new financial guidance for 2021, which includes guidance for year-end cash of greater than $400M, Beatty tells investors in a research note. The analyst believes this suggests a "meaningful commitment to keep opex controlled during 2021." He also increased the probability of approval of tradipitant for gastroparesis to 30% from 10%.

ShowHide Related Items >><<
VNDA Vanda Pharmaceuticals
$15.43 /

-0.01 (-0.06%)

VNDA Vanda Pharmaceuticals
$15.43 /

-0.01 (-0.06%)

01/14/21 Citi
Vanda Pharmaceuticals downgraded to Neutral from Buy at Citi
12/03/20 Jefferies
Vanda Pharmaceuticals price target raised to $18 from $16 at Jefferies
10/29/20 Citi
Vanda Pharmaceuticals upgraded to Buy from Neutral at Citi
06/09/20 Citi
Vanda downgraded to Neutral on FDA dispute at Citi
VNDA Vanda Pharmaceuticals
$15.43 /

-0.01 (-0.06%)

VNDA Vanda Pharmaceuticals
$15.43 /

-0.01 (-0.06%)

Downgrade
Vanda Pharmaceuticals downgraded to Neutral from Buy at Citi » 06:32
01/14/21
01/14
06:32
01/14/21
06:32
VNDA

Vanda Pharmaceuticals

$14.01 /

-0.14 (-0.99%)

Citi analyst Joel Beatty…

Citi analyst Joel Beatty downgraded Vanda Pharmaceuticals to Neutral from Buy with an unchanged price target of $14. The stock is up 50% since September, with relatively little change to the company's fundamental value, Beatty tells investors in a research note. The analyst anticipates "relatively little downside" to Vanda shire over the coming months but also "relatively little upside."

ShowHide Related Items >><<
VNDA Vanda Pharmaceuticals
$14.01 /

-0.14 (-0.99%)

VNDA Vanda Pharmaceuticals
$14.01 /

-0.14 (-0.99%)

12/03/20 Jefferies
Vanda Pharmaceuticals price target raised to $18 from $16 at Jefferies
10/29/20 Citi
Vanda Pharmaceuticals upgraded to Buy from Neutral at Citi
06/09/20 Citi
Vanda downgraded to Neutral on FDA dispute at Citi
06/09/20 Citi
Vanda Pharmaceuticals downgraded to Neutral from Buy at Citi
VNDA Vanda Pharmaceuticals
$14.01 /

-0.14 (-0.99%)

VNDA Vanda Pharmaceuticals
$14.01 /

-0.14 (-0.99%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.